CORRECTED-UPDATE 1-Novo Nordisk hijacks Pfizer with bid for US biotech Metsera

Metsera, Inc. 0.00%
Pfizer Inc. +1.28%
Dow Jones Industrial Average +0.22%
S&P 500 index +0.19%
NASDAQ +0.31%

Metsera, Inc.

MTSR

70.50

0.00%

Pfizer Inc.

PFE

26.03

+1.28%

Dow Jones Industrial Average

DJI

47954.99

+0.22%

S&P 500 index

SPX

6870.40

+0.19%

NASDAQ

IXIC

23578.13

+0.31%

Corrects in paragraphs 1 and 2 to say September, not 'last week'

- Denmark's Novo Nordisk NOVOb.CO said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera MTSR.O, after Pfizer PFE.N in September made an offer for the company.

Novo said it had offered $56.50 per share in cash for Metsera, corresponding to an enterprise value of $6 billion, while Pfizer in September said it would pay $47.50 per share in cash, representing $4.9 billion in enterprise value.

Both Novo and Metsera also offered contingent value rights (CVRs) that could add several billion dollars to the purchase price, based on the achievement of clinical and regulatory milestones.


(Reporting by Louise Breusch Rasmussen and Jacob Gronholt-Pedersen, editing by Terje Solsvik)

((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via